CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents
Results From the TAXUS-IV Trial
Duane S. Pinto, MD, FACC*,*,
Gregg W. Stone, MD, FACC ,
Stephen G. Ellis, MD, FACC ,
David A. Cox, MD, FACC ,
James Hermiller, MD, FACC||,
Charles O’Shaughnessy, MD, FACC¶,
J. Tift Mann, MD, FACC#,
Roxana Mehran, MD, FACC,
Yingbo Na, MSc,
Mark Turco, MD, FACC**,
Ronald Caputo, MD, FACC,
Jeffrey J. Popma, MD, FACC,
Donald E. Cutlip, MD, FACC*,
Mary E. Russell, MD, FACC,
David J. Cohen, MD, MSc* for the TAXUS-IV Investigators
* Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York
Cleveland Clinic Foundation, Cleveland, Ohio
Mid Carolina Cardiology, Charlotte, North Carolina
|| St. Vincent’s Hospital, Indianapolis, Indiana
¶ Elyria Memorial Hospital, Elyria, Ohio
# WakeMed, Raleigh, North Carolina
** Washington Adventist Hospital, Tacoma Park, Maryland
St. Joseph’s Hospital, Syracuse, New York
Brigham and Women’s Hospital, Boston, Massachusetts
Boston Scientific Corporation, Natick, Massachusetts
Manuscript received November 18, 2005;
revised manuscript received February 22, 2006,
accepted February 28, 2006.
* Reprint requests and correspondence: Dr. Duane S. Pinto, Division of Cardiology, Beth Israel Deaconess Medical Center, 1 Deaconess Road, Boston, Massachusetts 02115. (Email: dpinto{at}bidmc.harvard.edu).
OBJECTIVES: The objectives of the study were to evaluate the effect of angiographic follow-up on revascularization rates in the TAXUS-IV trial and to determine whether the relative benefit of paclitaxel-eluting stent implantation compared with bare metal stent implantation was modified by angiographic follow-up.
BACKGROUND: Although several clinical trials have demonstrated that drug-eluting stents (DES) reduce restenosis compared with bare-metal stents (BMS), virtually all of these studies have incorporated angiographic follow-up.
METHODS: In the TAXUS-IV trial, 1,314 percutaneous coronary intervention patients were randomized to receive paclitaxel-eluting stents (PES) (n = 662) or identical-appearing BMS (n = 652). Clinical outcomes were compared, stratified by assignment to angiographic follow-up or clinical follow-up alone.
RESULTS: Compared with clinical follow-up alone, angiographic follow-up patients had a significantly higher rate of target vessel revascularization (TVR) at 1 year (adjusted hazard ratio [HR] 1.46; p = 0.04), with similar relative increases in PES and BMS patients. Because PES reduced TVR by  60% regardless of type of follow-up, assignment to angiographic follow-up tended to overestimate the absolute benefit of PES relative to clinical follow-up alone. In contrast, assessment of end points immediately before the time of follow-up angiography led to substantial underestimation of the absolute benefit of PES implantation.
CONCLUSIONS: Performance of mandatory angiographic follow-up increases rates of TVR among patients receiving both BMS and PES and overestimates the absolute clinical benefits of PES relative to clinical follow-up alone. Nonetheless, PES substantially reduces TVR regardless of assignment to mandatory angiographic follow-up or not. Future studies designed to determine the true clinical benefits of DES should either forgo routine angiographic follow-up or separate the time of repeat angiography from the primary clinical end point by as long as possible.
|
Abbreviations and Acronyms
| | BMS = bare-metal stent | | DES = drug-eluting stent | | PCI = percutaneous coronary intervention | | PES = paclitaxel-eluting stent | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
G. W. Stone, S. G. Ellis, A. Colombo, E. Grube, J. J. Popma, T. Uchida, J. S. Bleuit, K. D. Dawkins, and M. E. Russell
Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents: Final 5-Year Analysis From the TAXUS Clinical Trial Program
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
530 - 542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, L. Mauri, J. J. Popma, M. A. Turco, P. A. Gurbel, P. J. Fitzgerald, and M. B. Leon
Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
543 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kaneda, J. Ako, and M. Terashima
Serial Intravascular Ultrasound Examinations and Clinical Outcome
J. Am. Coll. Cardiol.,
November 16, 2010;
56(21):
1764 - 1764.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, H. Parise, B. Witzenbichler, A. Kirtane, G. Guagliumi, J. Z. Peruga, B. R. Brodie, D. Dudek, M. Mockel, A. J. Lansky, et al.
Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up: 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
J. Am. Coll. Cardiol.,
November 2, 2010;
56(19):
1597 - 1604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehilli, R. A. Byrne, K. Tiroch, S. Pinieck, S. Schulz, S. Kufner, S. Massberg, K.-L. Laugwitz, A. Schomig, A. Kastrati, et al.
Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study
J. Am. Coll. Cardiol.,
June 15, 2010;
55(24):
2710 - 2716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Kim, D.-W. Park, W.-J. Kim, J.-Y. Lee, S.-C. Yun, S.-J. Kang, S.-W. Lee, C. W. Lee, M.-K. Hong, S.-W. Park, et al.
Impact of the Extent of Coronary Artery Disease on Outcomes After Revascularization for Unprotected Left Main Coronary Artery Stenosis
J. Am. Coll. Cardiol.,
June 8, 2010;
55(23):
2544 - 2552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. Uretsky
IIb or Not IIb? Toward a Rational Application of Left Main Stenting
J. Am. Coll. Cardiol.,
June 8, 2010;
55(23):
2553 - 2555.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Byrne, A. Kastrati, K. Tiroch, S. Schulz, J. Pache, S. Pinieck, S. Massberg, M. Seyfarth, K.-L. Laugwitz, K. A. Birkmeier, et al.
2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents
J. Am. Coll. Cardiol.,
June 8, 2010;
55(23):
2536 - 2543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Uchida, J. Popma, G. W. Stone, S. G. Ellis, M. A. Turco, J. A. Ormiston, T. Muramatsu, M. Nakamura, S. Nanto, H. Yokoi, et al.
The Clinical Impact of Routine Angiographic Follow-Up in Randomized Trials of Drug-Eluting Stents: A Critical Assessment of "Oculostenotic" Reintervention in Patients With Intermediate Lesions
J. Am. Coll. Cardiol. Intv.,
April 1, 2010;
3(4):
403 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, A. Farb, and A. B. Boam
Percutaneous Coronary Intervention in Perspective: Drug-Eluting Stents as a Model for Regulatory Review
Circ Cardiovasc Interv,
December 1, 2009;
2(6):
574 - 579.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Ellis, G. W. Stone, D. A. Cox, J. Hermiller, C. O'Shaughnessy, T. Mann, M. Turco, R. Caputo, P. J. Bergin, T. S. Bowman, et al.
Long-Term Safety and Efficacy With Paclitaxel-Eluting Stents: 5-Year Final Results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent)
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1248 - 1259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Kirtane, R. Patel, C. O'Shaughnessy, P. Overlie, B. McLaurin, S. Solomon, L. Mauri, P. Fitzgerald, J. J. Popma, D. E. Kandzari, et al.
Clinical and Angiographic Outcomes in Diabetics From the ENDEAVOR IV Trial: Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
967 - 976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Novack, D. Cutlip, N. Kleiman, M. Pencina, L. Mauri, C.-H. Yen, P. Berger, S. Goldberg, M. Kellett, R. Waksman, et al.
In-Hospital and 1-Year Outcomes Among Unselected Percutaneous Coronary Intervention Patients Treated With Either Sirolimus- or Paclitaxel-Eluting Stents: Results From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry
J. Am. Coll. Cardiol. Intv.,
August 1, 2009;
2(8):
767 - 775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Di Lorenzo, G. De Luca, R. Sauro, A. Varricchio, M. Capasso, T. Lanzillo, F. Manganelli, C. Mariello, F. Siano, M. R. Pagliuca, et al.
The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
515 - 523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ryan, W. Linde-Zwirble, L. Engelhart, L. Cooper, and D. J. Cohen
Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program
Circulation,
February 24, 2009;
119(7):
952 - 961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ortolani, F. Saia, R. M. T. Cooke, A. Marzocchi, M. Balducelli, A. Maresta, P. Marzaroli, P. Guastaroba, R. Grilli, G. Piovaccari, et al.
Response to Letters Regarding Article, "Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry"
Circulation,
October 28, 2008;
118(18):
e681 - e681.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Stettler, S. Allemann, S. Wandel, A. Kastrati, M. C. Morice, A. Schomig, M. E Pfisterer, G. W Stone, M. B Leon, J. S. d. Lezo, et al.
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
BMJ,
August 29, 2008;
337(aug29_3):
a1331 - a1331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, G. Campo, G. Percoco, L. Bolognese, C. Vassanelli, S. Colangelo, N. de Cesare, A. E. Rodriguez, M. Ferrario, R. Moreno, et al.
Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial
JAMA,
April 16, 2008;
299(15):
1788 - 1799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Kirtane, S. G. Ellis, K. D. Dawkins, A. Colombo, E. Grube, J. J. Popma, M. Fahy, M. B. Leon, J. W. Moses, R. Mehran, et al.
Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus: Pooled Analysis From 5 Randomized Trials
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
708 - 715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Pocock, A. J. Lansky, R. Mehran, J. J. Popma, M. P. Fahy, Y. Na, G. Dangas, J. W. Moses, T. Pucelikova, D. E. Kandzari, et al.
Angiographic Surrogate End Points in Drug-Eluting Stent Trials: A Systematic Evaluation Based on Individual Patient Data From 11 Randomized, Controlled Trials
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
23 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes
The Emperor's New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis
J. Am. Coll. Cardiol.,
October 2, 2007;
50(14):
1381 - 1385.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Marzocchi, F. Saia, G. Piovaccari, A. Manari, E. Aurier, A. Benassi, A. Cremonesi, G. Percoco, E. Varani, P. Magnavacchi, et al.
Long-Term Safety and Efficacy of Drug-Eluting Stents: Two-Year Results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) Multicenter Registry
Circulation,
June 26, 2007;
115(25):
3181 - 3188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Cutlip, S. Windecker, R. Mehran, A. Boam, D. J. Cohen, G.-A. van Es, P. Gabriel Steg, M.-a. Morel, L. Mauri, P. Vranckx, et al.
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Circulation,
May 1, 2007;
115(17):
2344 - 2351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
